1202884-94-3

Basic information

• Product Name: PI3K inhibitor
• Synonyms: PI3K inhibitor;Antitumor Drug;CAY10626;BenzaMide, N-[2-(diMethylaMino)ethyl]-N-Methyl-4-[[[[4-[4-(4-Morpholinyl)-7-(2,2,2-trifluoroethyl)-7H-pyrrolo[2,3-d]pyriMidin-2-yl]phenyl]aMino]carbonyl]aMino]-
• CAS NO: 1202884-94-3
• Molecular Formula: C₃₁H₃₅F₃N₈O₃
• Molecular Weight: 624.6566096
• EINECS: -0
• Mol File: 1202884-94-3.mol

Chemical Properties

• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• PKA: 13.74±0.70(Predicted)
• CAS DataBase Reference: PI3K inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: PI3K inhibitor(1202884-94-3)
• EPA Substance Registry System: PI3K inhibitor(1202884-94-3)

Safety Data

• Hazardous Substances Data: 1202884-94-3(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
PI3K inhibitor is used as a targeted therapy for the treatment of cancers with KRAS mutations. In preclinical studies, the combination of buparlisib (BKM120) with a MEK inhibitor (PD1056309) has shown significant synergistic activity in KRAS mutant NSCLC (non-small cell lung cancer) cell lines, indicating its potential in enhancing the effectiveness of cancer treatment for this specific patient population.

Upstream product

• 1202885-81-1 4-({[4-(7-(2,2,2-trifluoroethyl)-4-morpholin-4-yl-7H-pyrrolo-[2,3-d]pyrimidin-2-yl)phenyl]carbamoyl}amino)benzoic acid 
• 142-25-6 N,N',N'-trimethylenediamine 

Relevant articles and documents

(2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

The invention relates to 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds